HomeCompareELXMF vs JNJ

ELXMF vs JNJ: Dividend Comparison 2026

ELXMF yields 105263.16% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ELXMF wins by $8.064713171987811e+26M in total portfolio value
10 years
ELXMF
ELXMF
● Live price
105263.16%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.064713171987811e+26M
Annual income
$804,966,999,868,734,400,000,000,000,000,000.00
Full ELXMF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ELXMF vs JNJ

📍 ELXMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELXMFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELXMF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELXMF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELXMF
Annual income on $10K today (after 15% tax)
$8,947,368.42/yr
After 10yr DRIP, annual income (after tax)
$684,221,949,888,424,200,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ELXMF beats the other by $684,221,949,888,424,200,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELXMF + JNJ for your $10,000?

ELXMF: 50%JNJ: 50%
100% JNJ50/50100% ELXMF
Portfolio after 10yr
$4.0323565859939053e+26M
Annual income
$402,483,499,934,367,200,000,000,000,000,000.00/yr
Blended yield
99.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ELXMF
No analyst data
Altman Z
-1.9
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELXMF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELXMFJNJ
Forward yield105263.16%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$8.064713171987811e+26M$30.3K
Annual income after 10y$804,966,999,868,734,400,000,000,000,000,000.00$4,689.40
Total dividends collected$8.063727433132777e+26M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ELXMF vs JNJ ($10,000, DRIP)

YearELXMF PortfolioELXMF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,537,016$10,526,315.79$10,592$272.30+$10.53MELXMF
2$10,377,251,773$10,365,977,166.23$11,289$357.73+$10377.24MELXMF
3$9,552,044,282,229$9,540,940,622,831.33$12,123$472.89+$9552044.27MELXMF
4$8,217,919,074,277,338$8,207,698,386,895,354.00$13,141$629.86+$8217919074.26MELXMF
5$6,608,173,294,209,699,000$6,599,380,120,800,222,000.00$14,408$846.81+$6608173294209.68MELXMF
6$4,966,582,566,903,309,000,000$4,959,511,821,478,505,000,000.00$16,021$1,151.60+$4966582566903309.00MELXMF
7$3,488,939,161,660,980,000,000,000$3,483,624,918,314,393,500,000,000.00$18,122$1,588.22+$3488939161660979712.00MELXMF
8$2,290,823,651,613,942,000,000,000,000$2,287,090,486,710,964,800,000,000,000.00$20,930$2,228.20+$2.2908236516139422e+21MELXMF
9$1,405,904,046,772,744,300,000,000,000,000$1,403,452,865,465,517,400,000,000,000,000.00$24,792$3,191.91+$1.4059040467727442e+24MELXMF
10$806,471,317,198,781,100,000,000,000,000,000$804,966,999,868,734,400,000,000,000,000,000.00$30,274$4,689.40+$8.064713171987811e+26MELXMF

ELXMF vs JNJ: Complete Analysis 2026

ELXMFStock

Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. The company offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a natural ocular drainage system; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Asia Pacific, and internationally. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was founded in 1985 and is headquartered in Kent Town, Australia.

Full ELXMF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ELXMF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELXMF vs SCHDELXMF vs JEPIELXMF vs OELXMF vs KOELXMF vs MAINELXMF vs ABBVELXMF vs MRKELXMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.